FILING ANALYSIS · THURSDAY, NOVEMBER 5
IRONWOOD PHARMACEUTICALS INC IRWD — 8-K: Results of Operations and Financial Condition
positive
Ironwood Pharmaceuticals raises full-year 2026 financial guidance driven by LINZESS U.S. net sales growth and strong Q3 financial performance, with total revenue guidance increased to $485-$510 million and adjusted EBITDA guidance to over $350 million
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →